Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Keytruda
Pharma
AACR: Detailed data spark hope for Merck combo in NSCLC
Researchers plan to run biomarker analyses of patients in the KEYLYNK-008 trial to see whether any subsets may benefit from the addition of Lynparza.
Angus Liu
Apr 9, 2024 1:16pm
Merck’s Lynparza-Keytruda plan sputters in 2nd lung cancer trial
Mar 21, 2024 10:28am
Merck's Keytruda improves survival in cervical cancer trial
Mar 15, 2024 11:31am
GLP-1s on track to take drug sales throne from PD-1 inhibitors
Mar 15, 2024 10:54am
Merck claims digital crown, holding off challenge from AZ, BMS
Mar 15, 2024 10:30am
Merck challenges Johns Hopkins University's Keytruda patents
Mar 14, 2024 7:30am